GlassScriptPhysician profile
Samuel P Hamilton
NPI 1598481723
$1,965.34
in general payments reported to CMS, 2019-2025
15 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $265 · 2024: $519 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.14 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.75 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $329.84 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.94 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $271.03 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $217.16 | 2024-2025 | Sublocade |
| Axsome Therapeutics, INC. | $112.99 | 2023-2025 | Auvelity |
| Alkermes, INC. | $79.32 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.22 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $54.10 | 2023-2025 | Invega Sustenna |
| Novartis Pharmaceuticals Corporation | $38.60 | 2023 | |
| Lundbeck LLC | $38.28 | 2023-2024 | Abilify Maintena, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.40 | 2025 | Cobenfy |
| Braeburn INC. | $17.59 | 2025 | Brixadi |
| Ardelyx, INC. | $17.54 | 2025 | Ibsrela |
| Amgen INC. | $16.58 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.